N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination
N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers
N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
N2OFF (NASDAQ:NITO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
N2OFF regains compliance with Nasdaq minimum bid price requirement [Seeking Alpha]